Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

5.1K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

2.9K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
2.9K
Activation of Integrins01:15

Activation of Integrins

3.9K
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
3.9K
Integrins01:10

Integrins

4.3K
Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
4.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring the Influence of Chemical Exposures in Breast Cancer Disparities: High-Throughput Transcriptomic Analysis in Normal Breast Cells from Diverse Donors.

bioRxiv : the preprint server for biology·2026
Same author

Intermetallic nanoassemblies potentiate systemic STING activation.

Science (New York, N.Y.)·2026
Same author

Alternatively activated monocyte-derived myeloid cells promote extracellular pathogen persistence in pulmonary fungal granulomas.

The Journal of experimental medicine·2026
Same author

Author Correction: Mitochondrial complex II in intestinal epithelial cells regulates T cell-mediated immunopathology.

Nature immunology·2026
Same author

Dynamic Immune Cell Composition, Phenotypes, and Signaling in an Engineered Metastatic Niche.

Biotechnology and bioengineering·2026
Same author

Spatial organization of pulmonary type 2 inflammation by a macrophage-derived cholesterol metabolite.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Oct 20, 2025

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples
07:03

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples

Published on: October 2, 2020

4.7K

Targeting cancer stem cells via integrin β4.

Hannah E Dobson1, Shasha Ruan1,2, Alfred E Chang1

  • 1Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.

Oncotarget
|September 10, 2021
PubMed
Summary

Targeting integrin beta 4 (ITGB4) on cancer stem cells (CSCs) with immunotherapy reduced tumor growth and metastasis. This approach shows promise for treating various cancers, especially when combined with other treatments.

Keywords:
ITGβ4T cellsbispecific antibodycancer stem cellsdendritic cell vaccine

More Related Videos

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors
07:01

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors

Published on: March 1, 2020

10.4K
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.8K

Related Experiment Videos

Last Updated: Oct 20, 2025

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples
07:03

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples

Published on: October 2, 2020

4.7K
Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors
07:01

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors

Published on: March 1, 2020

10.4K
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.8K

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Integrins, like integrin beta 4 (ITGB4), are crucial for cell interactions and signaling, making them attractive targets for cancer therapy.
  • Cancer stem cells (CSCs) are resistant to conventional treatments and drive tumor metastasis and relapse.
  • ITGB4 is expressed on CSCs in models of metastatic mammary tumors and head and neck squamous cell carcinoma.

Purpose of the Study:

  • To investigate the efficacy of targeting ITGB4 on CSCs using immunological approaches.
  • To evaluate the potential of ITGB4-targeted therapies in reducing tumor growth, metastasis, and improving treatment outcomes.

Main Methods:

  • Two immunological strategies were employed: ITGB4 protein-pulsed dendritic cell (ITGB4-DC) vaccination and anti-CD3/anti-ITGB4 bispecific antibody (ITGB4 BiAb)-armed T cell adoptive transfer.
  • These therapies were tested in 4T1 mouse metastatic mammary tumor and SCC7 head and neck squamous cell carcinoma models.
  • The combination of ITGB4-targeted approaches with anti-PD-L1 immunotherapy was also assessed.

Main Results:

  • Both ITGB4-targeted therapies successfully reduced ITGB4-expressing CSCs.
  • Local tumor growth and lung metastasis were inhibited, mediated by ITGB4-specific immune responses.
  • Combining ITGB4-targeted therapies with anti-PD-L1 immunotherapy significantly enhanced treatment efficacy.
  • Increased serum concentrations of IFN-γ and IL-6 were observed.

Conclusions:

  • ITGB4 serves as a viable immunological target for CSCs.
  • ITGB4-targeted therapies demonstrate therapeutic potential across diverse tumor types expressing high ITGB4 levels.
  • Further research into ITGB4-targeted strategies, potentially including cytokine analysis, is warranted.